MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/neuonc/noaf025

Медицинская библиотека · Neuro-oncology · 2025

Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).

Fan Chengjuan, Hu Yuanyuan, Teng Chong, Lv Yanju, Song Xiaowei, Shen Weixi, Jiang Qiuying, Huang Dayong, Du Lina, Wang Guohua, Du Yang, Man Siqi, Zhang Zhichao, Zhang Jing, Li Li, Xin Tao

СтатьяКлиническое исследование I фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

Leptomeningeal metastases (LMs) are serious complications of non-small cell lung cancer (NSCLC). This study aimed to investigate the safety and efficacy of intrathecal immune checkpoint inhibitors (ICIs) in treating NSCLC-LM.

METHODS

We conducted this prospective phase 1 study (ChiCTR2200062245) using a traditional "3+3" design with intrathecal sintilimab (dose escalation 10, 20, 30, and 40 mg) for NSCLC-LM patients who had progressed from targeted therapy and intrathecal pemetrexed. The primary study endpoints were safety and recommended dose, and the secondary endpoints included clinical response rate, progression-free survival (PFS), intracranial progression-free survival (iPFS), and overall survival (OS).

RESULTS

No dose-limiting toxicity was found at 10, 20, 30, and 40 mg for intrathecal sintilimab. Therefore, sintilimab 40 mg was recommended for intrathecal injection. A total of 19 patients were enrolled in this study. The median age at diagnosis of LM was 53 years. The overall incidence of adverse events (AEs) was 68.4%, and rash (n = 4, 21.1%) was the most common AEs, which returned to normal after symptomatic treatment. As 1 patient was lost to follow-up and 18 patients could be evaluated for efficacy, the clinical response rate was 38.9% (7/18). Median PFS was 3.5 months (95% CI: 2.7-4.2 months), median iPFS was 3.5 months (95% CI: 1.3-5.6 months), and median OS was 11.5 months (95% CI: 0.0-25.4 months).

CONCLUSIONS

Intrathecal ICIs for NSCLC-LM patients are safe, and the recommended dose of sintilimab is 40 mg. Intrathecal sintilimab for NSCLC-LM failed from multi-line therapies, showed potential effectiveness in some patients, and is worthy of further study.

Для цитирования: Fan Chengjuan, Hu Yuanyuan, Teng Chong, Lv Yanju, Song Xiaowei, Shen Weixi, Jiang Qiuying, Huang Dayong, Du Lina, Wang Guohua, Du Yang, Man Siqi, Zhang Zhichao, Zhang Jing, Li Li, Xin Tao. Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).. Neuro-oncology. 2025. DOI: 10.1093/neuonc/noaf025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.